Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Myriad Genetics stock | 17.31

Own Myriad Genetics stock in just a few minutes.

Posted

Fact checked

Myriad Genetics, Inc is a diagnostics & research business based in the US. Myriad Genetics shares (MYGN) are listed on the NASDAQ and all prices are listed in US Dollars. Myriad Genetics employs 2,700 staff and has a trailing 12-month revenue of around USD$597.5 million.

How to buy shares in Myriad Genetics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Myriad Genetics. Find the stock by name or ticker symbol: MYGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Myriad Genetics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$17.31, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Myriad Genetics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Myriad Genetics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Myriad Genetics's share price?

Since the stock market crash in March caused by coronavirus, Myriad Genetics's share price has had significant negative movement.

Its last market close was USD$17.31, which is 11.91% down on its pre-crash value of USD$19.65 and 87.34% up on the lowest point reached during the March crash when the shares fell as low as USD$9.24.

If you had bought USD$1,000 worth of Myriad Genetics shares at the start of February 2020, those shares would have been worth USD$432.06 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$604.12.

Myriad Genetics share price

Use our graph to track the performance of MYGN stocks over time.

Myriad Genetics shares at a glance

Information last updated 2020-11-26.
Latest market close USD$17.31
52-week range USD$9.24 - USD$30.13
50-day moving average USD$14.8542
200-day moving average USD$13.5466
Wall St. target price USD$17.13
PE ratio 563.3333
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.06

Buy Myriad Genetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Myriad Genetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Myriad Genetics price performance over time

Historical closes compared with the close of $17.31 from 2020-11-16

1 week (2020-11-17) 0.12%
1 month (2020-10-27) 20.63%
3 months (2020-08-25) 20.63%
6 months (2020-05-23) N/A
1 year (2019-11-25) -35.31%
2 years (2018-11-23) -43.63%
3 years (2017-11-24) -47.96%
5 years (2015-11-25) -60.50%

Is Myriad Genetics under- or over-valued?

Valuing Myriad Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Myriad Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Myriad Genetics's P/E ratio

Myriad Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 563x. In other words, Myriad Genetics shares trade at around 563x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Myriad Genetics's PEG ratio

Myriad Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4001. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Myriad Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Myriad Genetics's EBITDA

Myriad Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.3 million.

The EBITDA is a measure of a Myriad Genetics's overall financial performance and is widely used to measure a its profitability.

Myriad Genetics financials

Revenue TTM USD$597.5 million
Gross profit TTM USD$452.5 million
Return on assets TTM -6.4%
Return on equity TTM -19.58%
Profit margin -32.49%
Book value $12.092
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Myriad Genetics shares

There are currently 9.5 million Myriad Genetics shares held short by investors – that's known as Myriad Genetics's "short interest". This figure is 3.6% up from 9.2 million last month.

There are a few different ways that this level of interest in shorting Myriad Genetics shares can be evaluated.

Myriad Genetics's "short interest ratio" (SIR)

Myriad Genetics's "short interest ratio" (SIR) is the quantity of Myriad Genetics shares currently shorted divided by the average quantity of Myriad Genetics shares traded daily (recently around 600570.42164884). Myriad Genetics's SIR currently stands at 15.89. In other words for every 100,000 Myriad Genetics shares traded daily on the market, roughly 15890 shares are currently held short.

However Myriad Genetics's short interest can also be evaluated against the total number of Myriad Genetics shares, or, against the total number of tradable Myriad Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Myriad Genetics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Myriad Genetics shares in existence, roughly 130 shares are currently held short) or 0.1895% of the tradable shares (for every 100,000 tradable Myriad Genetics shares, roughly 190 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Myriad Genetics.

Find out more about how you can short Myriad Genetics stock.

Myriad Genetics share dividends

We're not expecting Myriad Genetics to pay a dividend over the next 12 months.

Have Myriad Genetics's shares ever split?

Myriad Genetics's shares were split on a 2:1 basis on 26 March 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Myriad Genetics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Myriad Genetics shares which in turn could have impacted Myriad Genetics's share price.

Myriad Genetics share price volatility

Over the last 12 months, Myriad Genetics's shares have ranged in value from as little as $9.24 up to $30.13. A popular way to gauge a stock's volatility is its "beta".

MYGN.US volatility(beta: 1.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Myriad Genetics's is 1.4566. This would suggest that Myriad Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Myriad Genetics overview

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site